SWOG clinical trial number
SWOG-8005
Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Malignant Lymphomas
Closed
Phase
Abbreviated Title
Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Malignant Lymphomas
Activated
07/02/1980
Closed
05/10/1982
Research committees
Lymphoma
Publication Information Expand/Collapse
1984
Mitoxantrone in refractory NonHodgkin's lymphoma: A Southwest Oncology Group study
Mitoxantrone in refractory non-Hodgkin's lymphoma
1983
Mitoxantrone hydrochloride (NSC-301739) in lymphoma. A Southwest Oncology Group study
Mitoxantrone hydrochloride in lymphoma
Mitoxantrone hydrochloride in lymphoma
Mitoxantrone hydrochloride in hematologic malignancies: Southwest Oncology Group Phase II studies.
1981
Mitoxantrone Hydrochloride (NSC-30179) in hematologic malignancies
Other Clinical Trials
SWOG Clinical Trial Number
S2506
MOZART MZL: A Randomized Phase II Study with a Common Control Arm of Mosunetuzumab Monotherapy Evaluated Against Two Experimental Treatment Arms of Either Combination Mosunetuzumab and Zanubrutinib or Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma
Research Committee(s)
Lymphoma
Activated
08/18/2026
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA4232
A Randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Research Committee(s)
Lymphoma
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2308
Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
74%
Open
Phase